New hope for hair regrowth in rare immune disorder
NCT ID NCT05398809
Summary
This study is testing if the drug ruxolitinib can help regrow hair in people with a rare immune system disorder called APECED who have severe hair loss (alopecia areata). About 70 participants, aged 12 to 65, will take the drug as a pill twice a day for 8 months. Researchers will track hair regrowth, safety, and whether the drug helps other symptoms of APECED.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALOPECIA AREATA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.